PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
Status:
Withdrawn
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
An open-label, non-randomized, two-stage, multicenter study evaluating clinical efficacy,
safety and pharmacokinetics of PQR309 in patients with relapsed or refractory Primary Central
Nervous System Lymphoma (PCNSL).